TheBrief.Health

Deramiocel for Duchenne Muscular Dystrophy: FDA Review Raises Questions About Cardiac Benefit

Episode Summary

FDA advisers reviewed deramiocel’s cardiac evidence in Duchenne muscular dystrophy, weighing potential preservation of heart function against uncertain clinical benefit, safety, and long-term outcomes.